279 related articles for article (PubMed ID: 8353278)
21. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
22. [Soluble IL-6 receptors].
Jabłońska E
Postepy Hig Med Dosw; 1998; 52(2):133-8. PubMed ID: 9640977
[TBL] [Abstract][Full Text] [Related]
23. Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6-mediated functions.
Saito T; Taga T; Miki D; Futatsugi K; Yawata H; Kishimoto T; Yasukawa K
J Immunol Methods; 1993 Aug; 163(2):217-23. PubMed ID: 7689086
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
25. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis.
Padberg F; Feneberg W; Schmidt S; Schwarz MJ; Körschenhausen D; Greenberg BD; Nolde T; Müller N; Trapmann H; König N; Möller HJ; Hampel H
J Neuroimmunol; 1999 Oct; 99(2):218-23. PubMed ID: 10505978
[TBL] [Abstract][Full Text] [Related]
26. Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling.
Sui X; Tsuji K; Ebihara Y; Tanaka R; Muraoka K; Yoshida M; Yamada K; Yasukawa K; Taga T; Kishimoto T; Nakahata T
Blood; 1999 Apr; 93(8):2525-32. PubMed ID: 10194431
[TBL] [Abstract][Full Text] [Related]
27. Interactions between oncostatin M and the IL-6 signal transducer, gp130.
Liu J; Modrell B; Aruffo A; Scharnowske S; Shoyab M
Cytokine; 1994 May; 6(3):272-8. PubMed ID: 8054483
[TBL] [Abstract][Full Text] [Related]
28. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
29. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD.
Memoli B; Grandaliano G; Soccio M; Postiglione L; Guida B; Bisesti V; Esposito P; Procino A; Marrone D; Michael A; Andreucci M; Schena FP; Pertosa G
J Am Soc Nephrol; 2005 Apr; 16(4):1099-107. PubMed ID: 15716332
[TBL] [Abstract][Full Text] [Related]
30. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
32. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.
Pignatti P; Ciapponi L; Galle P; Hansen MB; Massa M; Meazza C; Paonessa G; Novick D; Ciliberto G; Martini A; De Benedetti F
Clin Exp Immunol; 2003 Feb; 131(2):355-63. PubMed ID: 12562400
[TBL] [Abstract][Full Text] [Related]
33. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts.
Vermes C; Jacobs JJ; Zhang J; Firneisz G; Roebuck KA; Glant TT
J Biol Chem; 2002 May; 277(19):16879-87. PubMed ID: 11884403
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
35. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
[TBL] [Abstract][Full Text] [Related]
36. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.
Wolf J; Waetzig GH; Reinheimer TM; Scheller J; Rose-John S; Garbers C
Biochem Biophys Res Commun; 2016 Feb; 470(4):870-6. PubMed ID: 26809098
[TBL] [Abstract][Full Text] [Related]
37. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.
Hirota H; Izumi M; Hamaguchi T; Sugiyama S; Murakami E; Kunisada K; Fujio Y; Oshima Y; Nakaoka Y; Yamauchi-Takihara K
Heart Vessels; 2004 Sep; 19(5):237-41. PubMed ID: 15372299
[TBL] [Abstract][Full Text] [Related]
38. The soluble IL-6 receptors: serum levels and biological function.
Montero-Julian FA
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
[TBL] [Abstract][Full Text] [Related]
39. Establishment of the ELISA for murine soluble gp130, a signal transducer for the IL-6 family cytokine, and its detection in the ascitic fluids of tumor-bearing mice.
Matsuda T; Hirano T
Biochem Biophys Res Commun; 1994 Jul; 202(1):637-42. PubMed ID: 8037770
[TBL] [Abstract][Full Text] [Related]
40. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.
Taga T; Narazaki M; Yasukawa K; Saito T; Miki D; Hamaguchi M; Davis S; Shoyab M; Yancopoulos GD; Kishimoto T
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10998-1001. PubMed ID: 1438305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
